Latest & greatest articles for etanercept

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on etanercept or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on etanercept and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for etanercept

41. Etanercept

Etanercept USE OF ETANERCEPT IN PREGNANCY 0344 892 0909 USE OF ETANERCEPT IN PREGNANCY (Date of issue: July 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Etanercept is a human tumour necrosis factor (TNF) receptor p75 Fc fusion protein monoclonal antibody produced by recombinant DNA (...) technology. Etanercept is administered in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis where other systemic therapies are ineffective or unsuitable. Maternal autoimmune/inflammatory conditions are known to increase the risk of certain adverse pregnancy outcomes including spontaneous abortion, preterm delivery and low birth weight, and studies which include disease-matched control groups suggest

UK Teratology Information Service2014

42. Etanercept (Enbrel) - polyarthritis (rheumatoid factor positive or negative) in children

Etanercept (Enbrel) - polyarthritis (rheumatoid factor positive or negative) in children All Wales Medicines Strategy Group (AWMSG) - etanercept (Enbrel) | | Appraisal information Search and reports etanercept (Enbrel®) Reference No. 1437 Publication date: 13/12/2013 Appraisal information etanercept (Enbrel®) 10 mg powder and solvent for solution for injection etanercept (Enbrel®) 25 mg powder and solvent for solution for injection etanercept (Enbrel®) 50 mg solution for injection etanercept (...) (Enbrel®) 25 mg/ml powder and solvent for solution for injection etanercept (Enbrel®) 25 mg solution for injection Company: Pfizer Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 23/10/2013 AWMSG meeting date: 20/11/2013 Submission Type: Limited Submission Status: Superseded Advice No: 3513 Ministerial ratification: 06/12/2013 Current Progress Submission received NMG meeting AWMSG meeting Ministerial Ratification AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE

All Wales Medicines Strategy Group2013

43. Etanercept (Enbrel) for axial spondyloarthritis without radiographic evidence of ankylosing spondylitis

Etanercept (Enbrel) for axial spondyloarthritis without radiographic evidence of ankylosing spondylitis Etanercept (Enbrel) for axial spondyloarthritis without radiographic evidence of ankylosing spondylitis Etanercept (Enbrel) for axial spondyloarthritis without radiographic evidence of ankylosing spondylitis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation NIHR HSC. Etanercept (Enbrel) for axial spondyloarthritis without radiographic evidence of ankylosing spondylitis. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antirheumatic Agents; Humans; Spondylarthritis; Spondylitis, Ankylosing Language Published English Country of organisation England English summary An English language summary is available. Address

Health Technology Assessment (HTA) Database.2013

44. The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis 23979914 2014 10 31 2014 12 30 2016 12 15 1468-2060 73 12 2014 Dec Annals of the rheumatic diseases Ann. Rheum. Dis. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy (...) in rheumatoid arthritis. 2144-51 10.1136/annrheumdis-2013-203684 To determine if withdrawing methotrexate (MTX) after 6 months of combination etanercept (ETN)+MTX, in MTX-inadequate responders with active rheumatoid arthritis (RA), is non-inferior to continuing ETN+MTX. Tumour necrosis factor-inhibitor naïve RA patients with disease activity score 28 (DAS28)≥3.2, swollen joint count≥3, despite stable MTX, were treated with ETN+MTX for 6 months, followed by randomisation to either continue ETN+MTX or switch

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

45. Cost-effectiveness of treatment with etanercept for psoriasis in Sweden

Cost-effectiveness of treatment with etanercept for psoriasis in Sweden Cost-effectiveness of treatment with etanercept for psoriasis in Sweden Cost-effectiveness of treatment with etanercept for psoriasis in Sweden Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, Boggs R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study estimated the cost-effectiveness of intermittent treatment with etanercept (Enbrel) in patients with moderate to severe psoriasis. The authors concluded that etanercept was cost-effective compared to both non-systemic treatment and adalimumab, assuming a EUR 50,000 willingness-to-pay threshold. The study was reasonably well conducted and reported, but it was not clear that the treatment effect data

NHS Economic Evaluation Database.2013

47. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-utility of adalimumab, etanercept, and tocilizumab, as first biologic treatments for moderate-to-severe rheumatoid arthritis, after the failure of one or more traditional disease

NHS Economic Evaluation Database.2013

48. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. 23332236 2013 03 18 2013 03 22 2016 11 25 1474-547X 381 9870 2013 Mar 16 Lancet (London, England) Lancet Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. 918-29 (...) activity would be sustained with reduced doses or withdrawal of etanercept in patients with moderately active disease. In a randomised controlled trial, patients aged between 18 and 70 years with moderately active rheumatoid arthritis (disease activity score in 28 joints [DAS28] >3.2 and ≤5.1) despite treatment with methotrexate were enrolled at 80 centres in Europe, Latin America, Asia, and Australia between March 6, 2008, and Sept 9, 2009. To be eligible, patients had to have been receiving 15-25 mg

Lancet2013

49. Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study

Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study 22829691 2012 12 03 2013 02 01 2015 11 19 1462-0332 51 12 2012 Dec Rheumatology (Oxford, England) Rheumatology (Oxford) Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. 2164-9 10.1093/rheumatology (...) /kes188 To evaluate the prevention of joint destruction and clinical efficacy of low-dose etanercept (ETN) (25 mg/week) compared with standard-dose ETN (50 mg/week) in RA. In this prospective, randomized, open-label study, 70 patients were assigned to receive ETN at either 50 or 25 mg/week for 52 weeks. The primary endpoint was the variation in modified total Sharp score (mTSS), and secondary endpoints were variations in disease activity score in 28 joints (DAS-28), modified HAQ and adverse event rate

EvidenceUpdates2013

50. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness

Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost (...) effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Infliximab

Health Technology Assessment (HTA) Database.2012

52. Etanercept (Enbrel) - for the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents

Etanercept (Enbrel) - for the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents Published 14 May 2012 Product Update etanercept 10mg and 25mg powder and sterile water for solution for injection for paediatric use (Enbrel®) Pfizer Ltd (No: 782/12) 06 April 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission etanercept (Enbrel®) is accepted for restricted use within NHS Scotland. Indication under review: for the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. SMC restriction: use within specialist rheumatology services (including those working within the network

Scottish Medicines Consortium2012

53. Etanercept (Enbrel) - for the treatment of chronic severe plaque psoriasis in children and adolescents

Etanercept (Enbrel) - for the treatment of chronic severe plaque psoriasis in children and adolescents

Scottish Medicines Consortium2012

54. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred

NIHR HTA programme2011

55. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose

NIHR HTA programme2011

56. Cost utility analysis based on a head-to-head phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective

Cost utility analysis based on a head-to-head phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective Cost utility analysis based on a head-to-head phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective Cost utility analysis based on a head-to-head phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis (...) : a Canadian perspective Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study evaluated the cost-effectiveness of ustekinumab compared with etanercept among adults with moderate

NHS Economic Evaluation Database.2011

57. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams (...) K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment

Health Technology Assessment (HTA) Database.2011

58. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF (...) , etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation . Health Technology Assessment 2011; 15(14): 1-278 Authors' conclusions Study found rituximab and abatacept to be more effective compared with supportive care (including ongoing disease-modifying antirheumatic drugs) in rheumatoid arthritis after failure of a TNF inhibitor. Use of an alternative TNF inhibitor in this patient population

Health Technology Assessment (HTA) Database.2011

59. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment

Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of etanercept combined with methotrexate, followed by a dose reduction, for patients with early active rheumatoid arthritis. The authors concluded that this combination and dose reduction, compared with methotrexate alone, was cost-effective. The study

NHS Economic Evaluation Database.2011

60. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | Guidance and guidelines | NICE Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance [TA199] Published date: 25 August 2010 Share Guidance on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults (...) . The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication. This guidance replaces NICE technology appraisal guidance on: etanercept and infliximab for the treatment of psoriatic arthritis (TA104) and adalimumab for the treatment of psoriatic arthritis (TA125). Guidance development process Next review date: This guidance will be reviewed if there is new evidence. Your responsibility The recommendations

National Institute for Health and Clinical Excellence - Technology Appraisals2010